| APDN:Applied DNA Sciences Inc * | | Charting | News | Options |
*Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements |
||||||||||||
| ||||||||||||||
| ||||||||||||||
| ||||||||||||||
1.63% $0.01
 Markets |
 Portfolio |
| |
| |
|
| |
|
|
|
|||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||
|
| Latest Story |
|
| Applied DNA Enters into Agreement with Alphazyme for Scale-Up Manufacturing of its Proprietary Linea(TM) RNAP, Progresses Towards GMP Linea(TM) IVT Production Start |
|
| ACCESSWIRE |
|
- Project To Increase RNAP Manufacturing Capacity and Reduce Unit Costs of Goods - - Project Slated for Completion Coincident with Company's Planned Initiation of GMP Manufacturing for Linea ™ DNA IVT Templates - |
| Full Story → |
|
| Headline News |
|
| Applied DNA to Showcase Linea(TM) DNA and Linea(TM) IVT Platforms at 24th Annual World Vaccine Congress |
| 10:01a ET March 14 '24 ACCESSWIRE |
|
|
| Applied DNA Announces First Quarter Fiscal Year 2024 Financial Results |
| 4:08p ET February 8 '24 ACCESSWIRE |
|
|
| Applied DNA to Report First Quarter Fiscal 2024 Financial Results on Thursday, February 8, 2024 |
| 1:01p ET February 5 '24 ACCESSWIRE |
|
| More News → |
| ||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
| April 19 '24. Markets Closed. | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
| Previous data from yesterday, April 18 '24. | ||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
| Historical Price Performance | ||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
|
Market data provided by 
News provided by   |
9.42%
